Townsquare Capital LLC Buys 1,744 Shares of Masimo Corporation (NASDAQ:MASI)

Townsquare Capital LLC boosted its stake in shares of Masimo Corporation (NASDAQ:MASI - Free Report) by 21.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,870 shares of the medical equipment provider's stock after purchasing an additional 1,744 shares during the period. Townsquare Capital LLC's holdings in Masimo were worth $1,644,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. LPL Financial LLC lifted its stake in shares of Masimo by 22.9% in the 4th quarter. LPL Financial LLC now owns 4,310 shares of the medical equipment provider's stock worth $712,000 after purchasing an additional 803 shares during the period. Franklin Resources Inc. lifted its stake in shares of Masimo by 73.8% in the 4th quarter. Franklin Resources Inc. now owns 2,925 shares of the medical equipment provider's stock worth $484,000 after purchasing an additional 1,242 shares during the period. Envestnet Asset Management Inc. lifted its stake in shares of Masimo by 17.3% in the 4th quarter. Envestnet Asset Management Inc. now owns 31,107 shares of the medical equipment provider's stock worth $5,142,000 after purchasing an additional 4,579 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of Masimo by 3,703.7% in the 4th quarter. Russell Investments Group Ltd. now owns 19,703 shares of the medical equipment provider's stock worth $3,257,000 after purchasing an additional 19,185 shares during the period. Finally, Invesco Ltd. lifted its stake in shares of Masimo by 226.4% in the 4th quarter. Invesco Ltd. now owns 277,960 shares of the medical equipment provider's stock worth $45,947,000 after purchasing an additional 192,802 shares during the period. Institutional investors own 85.96% of the company's stock.

Masimo Price Performance

NASDAQ MASI opened at $155.96 on Thursday. Masimo Corporation has a 12 month low of $107.98 and a 12 month high of $194.88. The stock has a market cap of $8.47 billion, a price-to-earnings ratio of -18.31 and a beta of 1.21. The company's 50 day moving average is $161.70 and its two-hundred day moving average is $164.24. The company has a current ratio of 2.14, a quick ratio of 1.61 and a debt-to-equity ratio of 0.57.

Masimo (NASDAQ:MASI - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The medical equipment provider reported $1.33 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.22 by $0.11. Masimo had a negative net margin of 24.85% and a positive return on equity of 26.54%. The business had revenue of $370.90 million during the quarter, compared to analyst estimates of $368.65 million. During the same period last year, the firm posted $0.86 EPS. The company's revenue was up 7.7% on a year-over-year basis. As a group, research analysts anticipate that Masimo Corporation will post 4.1 earnings per share for the current year.

Insider Transactions at Masimo

In related news, Director William R. Jellison acquired 3,000 shares of the business's stock in a transaction on Monday, August 11th. The stock was acquired at an average cost of $145.98 per share, with a total value of $437,940.00. Following the acquisition, the director directly owned 4,790 shares in the company, valued at $699,244.20. This represents a 167.60% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 9.70% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several brokerages have recently weighed in on MASI. Wells Fargo & Company lowered their price objective on shares of Masimo from $205.00 to $190.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. BTIG Research reiterated a "buy" rating on shares of Masimo in a research note on Monday, July 14th. Raymond James Financial lowered their price objective on shares of Masimo from $204.00 to $185.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Wall Street Zen cut shares of Masimo from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Finally, Piper Sandler raised their target price on shares of Masimo from $200.00 to $210.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $193.60.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.